Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

3 Horrendous Health-Care Stocks This Week: Impax Laboratories Inc (IPXL), Depomed Inc (DEPO), AngioDynamics, Inc. (ANGO)

Page 1 of 2

Mr. Market was a happy camper this week, with the Dow setting all-time highs. However, a few stocks in the health-care sector didn’t join the party. Here are three of the most horrendous performers for the week.

Manufacturing a downturn
If at first you don’t succeed, try, try again. But what if you try and still don’t succeed? That’s the question facing specialty pharmaceutical company Impax Laboratories Inc (NASDAQ:IPXL). Shares plunged nearly 17% this week on news that a second inspection of a manufacturing facility by the Food and Drug Administration still found problems. It could have been even worse — at one point during the week, shares were down nearly 27%.

Impax Laboratories Inc (NASDAQ:IPXL)An earlier inspection of the Hayward, Calif., facility was conducted in March 2012. Three of the issues cited in the most recent inspection were initially found last year but had not been corrected. The FDA also found nine new issues.

This situation has proved to be quite embarrassing for Impax Laboratories Inc (NASDAQ:IPXL) and costly for its shareholders. The company stated that it is “working diligently” to address the problems and intends to respond to the FDA soon.

Missing big
Medical-device maker AngioDynamics, Inc. (NASDAQ:ANGO) saw its shares tumble 12% this week. The company badly missed analyst estimates for revenue and earnings in the last quarter.

The numbers were only preliminary, but they didn’t look great. AngioDynamics, Inc. (NASDAQ:ANGO) said that revenue would probably come in at $82 million for the quarter ended Feb. 28. Analysts were expecting close to $88 million. The company expects to post earnings of $0.04 to $0.06 per share. Even the high end of that range is still well below the $0.09 per share analysts expect.

What happened? AngioDynamics, Inc. (NASDAQ:ANGO) CEO Joseph DeVivo said the company expected to build momentum in the quarter but was caught off-guard by softness in elective procedure volumes. However, DeVivo also maintained that the poor results should be temporary.

Feeling heat
Shareholders in Depomed Inc (NASDAQ:DEPO) felt the heat this week after an FDA advisory panel rejected hot-flash drug Sefelsa. The stock dropped 9.5% on the decision.

The advisory panel voted 12-2 against recommending Sefelsa. The panel thought Depomed Inc (NASDAQ:DEPO)’s three studies didn’t show that the drug actually reduced hot flashes in menopausal women. Without solid efficacy results, the panel thought the benefits weren’t sufficient to overcome safety issues with Sefelsa. Side effects for the drug include dizziness, fatigue, balance problems, and increased suicidal thoughts.

Page 1 of 2

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!